Deltaclinical

JANUARY 13, 2023

Home visits for clinical trials are becoming increasingly popular, as they offer a number of distinct benefits for both the patient and the provider. In this blog post, we’ll explore the top ten benefits of clinical trial home visits to help you make an informed decision about whether or not this type of service is right for your study.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Allergies 130

Deltaclinical

JANUARY 13, 2023

Home visits for clinical trials are becoming increasingly popular, as they offer a number of distinct benefits for both the patient and the provider. In this blog post, we’ll explore the top ten benefits of clinical trial home visits to help you make an informed decision about whether or not this type of service is right for your study.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Allergies 130

Deltaclinical

JANUARY 13, 2023

Home visits for clinical trials are becoming increasingly popular, as they offer a number of distinct benefits for both the patient and the provider. In this blog post, we’ll explore the top ten benefits of clinical trial home visits to help you make an informed decision about whether or not this type of service is right for your study.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Allergies 130

Deltaclinical

JANUARY 13, 2023

Home visits for clinical trials are becoming increasingly popular, as they offer a number of distinct benefits for both the patient and the provider. In this blog post, we’ll explore the top ten benefits of clinical trial home visits to help you make an informed decision about whether or not this type of service is right for your study.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Allergies 130

DM Clinical Research

APRIL 30, 2021

And while this means that most of us can get outside and enjoy the nice weather, it means something different to allergy sufferers. If you have seasonal allergies, then you know how painful and annoying your symptoms can be. Certain symptoms might have you wondering- is it allergies or COVID? Is it Allergies or COVID symptoms?

Allergies 40

Allergies Clinical Research Vaccination Vaccine 40

Rethinking Clinical Trials

FEBRUARY 2, 2023

Russell, MD Assistant Professor, Department of Medicine Co-Director, Program in Medical ICU Research Division of Pulmonary, Allergy & Critical Care Medicine Assistant Medical Director, Birmingham Veterans Affairs Medical Center MICU University of Alabama at Birmingham Heersink School of Medicine Matthew W.

Trials 130

Trials Clinical Trials Clinical Trials Medicine 130

The Pharma Data

JANUARY 7, 2021

This clearance is a pivotal regulatory milestone that further supports Camallergy’s leadership and capabilities in the field of peanut allergy immunotherapy with the only cGMP-certified manufacturing facility in Europe producing peanut oral immunotherapy,” said Sherden Timmins, Chief Technology Officer. 8, 2021 07:00 UTC. About Camallergy.

Allergies 52

Allergies Manufacturing Production Clinical Trials 52

Drug Discovery World

FEBRUARY 26, 2024

The US Food and Drug Administration (FDA) has approved monoclonal antibody Xolair (omalizumab) for immunoglobulin E-mediated food allergy in some adults and children one year or older for the reduction of allergic reactions (Type I).

FDA Approval 52

FDA Approval Allergies Protein Antibody 52

XTalks

MAY 17, 2024

This day isn’t just a reminder of the medical challenge to find a safe and effective HIV vaccine, but also a tribute to the undertaking that has both challenged and intrigued researchers for over three decades. The Current Landscape of HIV Vaccine Research Today, the landscape of HIV research is filled with innovation.

Vaccination 52

Vaccination Vaccine Research Immune Response 52

Drug Discovery World

SEPTEMBER 25, 2023

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. With each new universal influenza vaccine candidate and clinical trial, we take another step closer to that goal,” said Acting NIAID Director Hugh Auchincloss.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Clinical Trial Podcast

SEPTEMBER 26, 2022

To answer these two questions, regulatory authorities around the world require medical product manufacturers to conduct Phase I, also known as early phase clinical trials. Cohen to the Clinical Trial Podcast. The post Complexity in Early Phase Clinical Trials with Dr. Oren Cohen? Sponsor: This podcast is brought to you by Calyx.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Clinical Research 98

Medical Xpress

DECEMBER 22, 2022

The study analyzed data from two phase 3 clinical trials and involved an international group of researchers, including those from Children's Hospital of Philadelphia (CHOP).

Antibody 75

Antibody Allergies Clinical Trials Clinical Trials 75

Drug Discovery World

MAY 18, 2023

A clinical trial of an experimental universal influenza vaccine developed by researchers at the National Institute of Allergy and Infectious Diseases’ (NIAID) Vaccine Research Center (VRC) has begun enrolling volunteers at Duke University in Durham, North Carolina.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Medical Xpress

JANUARY 30, 2023

A newly published paper in The Lancet shows that an experimental vaccine against Marburg virus (MARV) was safe and induced an immune response in a small, first-in-human clinical trial.

Vaccination 104

Vaccination Vaccine Immune Response Allergies 104

Drug Discovery World

MAY 17, 2023

A first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body has begun. The trial is testing the safety, tolerability and processing in the body of escalating doses of the investigational drug product HOPO 14-1 in healthy adults.

Contamination 52

Contamination Trials Drugs Allergies 52

Delveinsight

AUGUST 6, 2020

Zydus starts phase 2 COVID-19 vaccine trial after clearing safety test. Zydus Cadila has finished a phase 1 clinical trial of its COVID-19 vaccine ZyCoV-D, setting it up to move straight into a 1,000-subject phase 2 study. Zydus has only said that the vaccine was well tolerated by people who received it in the first phase of the trial.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

XTalks

SEPTEMBER 21, 2023

announced that the first participant has been dosed in a new Phase I trial for an innovative HIV vaccine candidate, VIR-1388. The trial’s primary objective is to assess the safety of VIR-1388 and its capacity to stimulate a specific immune response against HIV in study participants. Vir Biotechnology, Inc.,

Vaccination 59

Vaccination Vaccine Trials Clinical Trials 59

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. This marks the second time one of Janssen’s HIV vaccines failed after another showed disappointing results in the Phase IIb Imbokodo trial in August 2021.

Vaccination 293

Vaccination Vaccine Antibody Trials 293

Drug Discovery World

DECEMBER 6, 2022

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial. . The Phase I trial (IAVI G001) tested the first stage in a multi-stage HIV vaccine regimen the researchers are developing.

Vaccination 52

Vaccination Vaccine Trials Antibody 52

The Pharma Data

OCTOBER 27, 2020

The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) has halted a clinical trial evaluating Eli Lilly’s investigational monoclonal antibody, LY-CoV555 (bamlanivimab), in combination with remdesivir for the treatment of COVID-19 patients. Source link.

Antibody 52

Antibody Trials Allergies Clinical Trials 52

Drug Discovery World

JULY 19, 2022

An early-stage clinical trial has been launched in the US investigating a vaccine against Nipah virus infection. . The clinical trial has been launched by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate an investigational vaccine to prevent infection with Nipah virus.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Vaccination 52

XTalks

AUGUST 13, 2020

and BioNTech’s lead vaccine candidate in a Phase III trial being conducted at sites in California and Oregon. The company announced that it commenced the Phase III clinical trial to evaluate the investigational COVID-19 vaccine this week. Related: Pfizer and BioNTech’s COVID-19 Vaccine Shows Positive Early Trial Results.

Vaccination 89

Vaccination Vaccine Trials Clinical Trials 89

Drug Discovery World

JANUARY 2, 2024

We are pleased to have these exciting data published in the prestigious, peer-reviewed journal Allergy ,” said Brian Wong, President and CEO of RAPT Therapeutics. We look forward to reporting top-line data from our Phase IIb trial in atopic dermatitis in mid-2024 and continuing to progress enrolment in our Phase IIa trial in asthma.”

Allergies 59

Allergies Trials Research Drugs 59

Trialfacts

JULY 20, 2022

About the Research Center: Location. Research Center: DaVinci Research, LLC. Lead Researcher: Rose Khalatyan, MPH, CCRP. Sinus disease ranges from chronic rhinosinusitis, nasal polyps, and loss of smell, to pain, congestion, and allergies during seasonal changes. About the Research Center: DaVinci Research, LLC.

Research 52

Research Allergies Clinical Trials Clinical Trials 52

Trialfacts

JULY 5, 2022

Researchers are exploring a potential cancer treatment. Researchers are inviting healthy males to join this paid clinical trial. If you are generally healthy and want to advance medical research, consider joining! Participants may help researchers further develop cancer treatments. Why Participate? . Your Rights.

Research 52

Research Clinical Research Allergies Clinical Trials 52

The Pharma Data

OCTOBER 22, 2020

The randomized, placebo-controlled trial is being conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and HHS’ Biomedical Advanced Research and Development Authority.

Vaccination 52

Vaccination Vaccine Trials Allergies 52

World of DTC Marketing

OCTOBER 6, 2021

In the first 29 days of the trial, no deaths were reported among the 385 patients who received the drug, while eight of the people who received a placebo died, according to the statement put out by Merck and Ridgeback Biotherapeutics, the two companies that are jointly launching it. million for CDC’s preclinical research; $39.7

Clinical Trials 198

Clinical Trials Clinical Trials Allergies Trials 198

Drug Discovery World

MAY 1, 2024

A single injection of an experimental monoclonal antibody called L9LS was 77% effective at preventing malaria infection in children in Mali, according to the results of a mid-stage clinical trial. In an earlier study, conducted in Mali by the same research group, a previously discovered antibody was highly protective against P.

Antibody 52

Antibody Clinical Trials Clinical Trials Scientist 52

Drug Discovery World

FEBRUARY 20, 2023

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, according to a recent report by analytics company Phesi. Results from the PROVENT Phase III trial showed a significant reduction in the risk of developing symptomatic Covid-19 and that the protection continued for at least six months.

Drug Trials 52

Drug Trials Trials Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JANUARY 8, 2023

There are at least six different biologics being studied in Phase III trials in COPD clinical programmes around the world. Results from a Phase III trial with Sanofi and Regeneron Pharmaceuticals’ IL-4/IL-13 monoclonal antibody (mAb) Dupixent (dupilumab) are expected by mid-2023, followed by others. Biologics: From asthma to COPD?

Antibody 298

Antibody Trials Clinical Trials Clinical Trials 298

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 37% of trial volunteers are from racial and ethnic minorities.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

pharmaphorum

JULY 12, 2022

Researchers in the US have started a clinical trial of a vaccine against Nipah virus, a serious infection caught from animals that has a fatality rate of between 40% and 70%, developed by mRNA specialist Moderna. The post NIH starts trial of Moderna’s mRNA Nipah virus vaccine appeared first on.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

The Pharma Data

MARCH 31, 2022

A Phase 2 clinical trial evaluating various additional COVID-19 booster shots has begun enrolling adult participants in the United States. The study, known as the COVID-19 Variant Immunologic Landscape (COVAIL) trial, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Immune Response 52

Delveinsight

AUGUST 27, 2020

The phase 1 study that is being run by the National Institute of Allergy and Infectious Diseases tests three dose levels of the vaccine, mRNA-1273, given in two injections a month apart in 120 adults. Moderna showed robust phase 1 results for its COVID-19 vaccine in adults up to 55 last month.

Vaccination 53

Vaccination Vaccine Research Trials 53

The Pharma Data

SEPTEMBER 1, 2020

AstraZeneca has started a Phase 3 trial of its experimental coronavirus vaccines in the US, making it the third company to start late-stage trials of a vaccine. . The trial will see participants receive either two doses of the vaccine or a placebo. Photo by Daniel Paquet from Regina, Canada.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

Pharmaceutical Technology

DECEMBER 16, 2022

Spearheaded by collaborations between non-profit groups and pharma players, new treatments are edging closer to late-stage trials in malaria and neglected tropical diseases such as sleeping sickness. However, Mosquirix’s efficacy is limited, while results from a Phase III licensure trial of R21 are expected this year.

Development 264

Development Drugs Vaccination Vaccine 264

pharmaphorum

FEBRUARY 9, 2021

An international trial led by US experts is to begin testing AstraZeneca’s long-acting antibody combination therapy to treat COVID-19. The combination known as AZD7442 is to be added to the phase 3 adaptive trial called ACTIV-3, where investigators add new sub-studies of investigational new agents.

Antibody 52

Antibody Trials Allergies Engineer 52